Marisa Wexler, MS, senior science writer —

The U.S. Food and Drug Administration (FDA) has granted fast track designation to PLN-74809, now in a Phase 2 clinical trial, as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is intended to help speed the development of treatments aiming to address unmet medical needs for serious…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Angion Biomedica plans to ask the U.S. Food and Drug Administration (FDA) for permission to start testing its experimental therapy ANG-3070 in people with idiopathic pulmonary fibrosis (IPF), the company announced. ANG-3070 is an oral medication designed to block the activity of multiple protein receptors that contribute to…

Ube Industries and HiLung are teaming up to advance HL001, an experimental therapy to prevent disease progression in idiopathic pulmonary fibrosis (IPF). The companies, both based in Japan, anticipate launching clinical studies of HL001 in people by March 2024. “This most recent agreement solidifies the collaboration between Ube Industries…

RXC007, an experimental oral treatment of idiopathic pulmonary fibrosis (IPF) being developed by Redx Pharma, continues to be safe and well-tolerated in a Phase 1 study in healthy volunteers, the company reported. “Clinical data from our Phase 1 study suggests that RXC007 is safe and well-tolerated at the drug doses…

Bridge Biotherapeutics has entered into an exclusive option-to-license agreement with Cellion BioMed to develop BBT-301, an experimental ion modulator therapy, as a potential treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. “We are highly excited to in-license BBT-301, a novel drug candidate for the treatment of fibrotic…

The China National Intellectual Property Administration has granted AdAlta a patent covering AD-214, the biotech company’s experimental therapy for idiopathic pulmonary fibrosis (IPF). The patent — number CN 107427574 B — entitled “CXCR4 binding molecules,” will expire in early January 2036. “China is now the second largest (and…

Boehringer Ingelheim Canada has finished negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) — a partnership between the country’s provincial, territorial and federal governments — for Ofev (nintedanib), the company’s approved oral medication for progressive fibrosing interstitial lung diseases (PF-ILD). The pCPA conducts negotiations with drug manufacturers for treatments…

A novel imaging biomarker identified via an artificial intelligence (AI)-powered analysis could help predict lung function and survival outcomes for people with idiopathic pulmonary fibrosis (IPF). Brainomix, a U.K.-based software company, is developing a number of AI-based tools to analyze different diseases, including one called e-ILD…

Patients with idiopathic pulmonary fibrosis (IPF) with chronic cough who are being treated with the investigational oral medication NP-120 (ifenprodil) in a small clinical trial tended to experience a reduction in coughing, according to the therapy’s developer Algernon Pharmaceuticals. The company is funding an open-label Phase 2…